본문 바로가기
KERD
논문KCI 등재

Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review

김성환|김애란|이종훈|이성종|이세원
대한암학회 (Korean Cancer Association)|2024.01|Cancer Research and Treatment|제56권 제1호|pp. 1-17|DOI 10.4143/crt.2023.562

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Uterine cervical neoplasmsPostoperativeExternal beam radiotherapyIntensity-modulated radiation therapyDefinitive
주제분류의학일반

초록

Radiotherapy (RT) is a fundamental modality in treatment of cervical cancer. With advancement of technology, conventional RT used for external beam radiotherapy (EBRT) for over half a century has been rapidly replaced with intensity-modulated radiation therapy (IMRT) especially during the last decade. This newer technique is able to differentiate the intensity of radiation within the same field, thus reduces the inevitable exposure of radiation to normal organs and enables better dose delivery to tumors. Recently, the American Society for Radiation Oncology has released a guideline for RT in cervical cancer. Although a section of the guideline recommends IMRT for the purpose of toxicity reduction, a thorough review of the literature is necessary to understand the current status of IMRT in cervical cancer. This narrative review updates the recent high-level evidences regarding the efficacy and toxicity of IMRT and provides a better understanding of the most innovative techniques currently available for EBRT enabled by IMRT.

Abstract

Radiotherapy (RT) is a fundamental modality in treatment of cervical cancer. With advancement of technology, conventional RT used for external beam radiotherapy (EBRT) for over half a century has been rapidly replaced with intensity-modulated radiation therapy (IMRT) especially during the last decade. This newer technique is able to differentiate the intensity of radiation within the same field, thus reduces the inevitable exposure of radiation to normal organs and enables better dose delivery to tumors. Recently, the American Society for Radiation Oncology has released a guideline for RT in cervical cancer. Although a section of the guideline recommends IMRT for the purpose of toxicity reduction, a thorough review of the literature is necessary to understand the current status of IMRT in cervical cancer. This narrative review updates the recent high-level evidences regarding the efficacy and toxicity of IMRT and provides a better understanding of the most innovative techniques currently available for EBRT enabled by IMRT.

참고문헌 (120)

  1. Arbyn M, "Estimates of incidence and mortality of cervi¬cal cancer in 2018 : a worldwide analysis", Lancet Glob Health, 8, pp.e191~e203 (2020)
  2. "Cervical cancer (version 1.2023)" (2023)[URL]
  3. Aronowitz JN, "Classics in brachy¬therapy : Margaret Cleaves introduces gynecologic brachy-therapy", Brachytherapy, 6, pp.293~297 (2007)
  4. Huh HD, "History of radiation therapy technology", Prog Med Phys, 31, pp.124~134 (2020)
  5. Gerstner N, "The benefit of Beam’s eye view based 3D treatment planning for cervical cancer", Radiother Oncol, 51, pp.71~78 (1999)
  6. Brahme A, "Solution of an integral equation encountered in rotation therapy", Phys Med Biol, 27, pp.1221~1229 (1982)
  7. Mundt AJ, "Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies", Int J Radiat Oncol Biol Phys, 52, pp.1330~1337 (2002)
  8. Gill BS, "National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer : the impact of new technological advancements", Int J Radiat Oncol Biol Phys, 90, pp.1083~1090 (2014)
  9. Portelance L, "Intensity-modulated radiation therapy(IMRT)reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation", Int J Radiat Oncol Biol Phys, 51, pp.261~266 (2001)
  10. Du XL, "Intensity-modulated radiation therapy for advanced cervical cancer : a comparison of dosimetric and clinical outcomes with conventional radiotherapy", Gynecol Oncol, 125, pp.151~157 (2012)
  11. Simpson DR, "Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin", Int J Radiat Oncol Biol Phys, 83, pp.e81~e86 (2012)
  12. Verma J, "Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer", Int J Radiat Oncol Biol Phys, 88, pp.357~362 (2014)
  13. Luo HC, "Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria(NCCN VS RTOG)", Br J Radiol, 91, pp.20170398~ (2018)
  14. Shih KK, "Impact of postoperative intensity-modulated radiation therapy(IMRT)on the rate of bowel obstruction in gynecologic malignancy", Gynecol Oncol, 143, pp.18~21 (2016)
  15. Chen MF, "Clinical outcome in posthysterectomy cervical cancer pati-ents treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy : comparison with conventional radiotherapy", Int J Radiat Oncol Biol Phys, 67, pp.1438~1444 (2007)
  16. Lin AJ, "Intensity modulated radiation therapy and image-guided adapted brachytherapy for cervix cancer", Int J Radiat Oncol Biol Phys, 103, pp.1088~1097 (2019)
  17. Chang Y, "Correlations between radiation dose in bone marrow and hematological toxicity in patients with cervical cancer : a comparison of 3DCRT, IMRT, and RapidARC", Int J Gynecol Cancer, 26, pp.770~776 (2016)
  18. Kidd EA, "Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer", Int J Radiat Oncol Biol Phys, 77, pp.1085~1091 (2010)
  19. Gandhi AK, "Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma : a prospective randomized study", Int J Radiat Oncol Biol Phys, 87, pp.542~548 (2013)
  20. Yu C, "A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer", Eur J Gynaecol Oncol, 36, pp.278~282 (2015)
  21. Naik A, "Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma : a randomized prospective study", Cancer Radiother, 20, pp.370~376 (2016)
  22. Lin Y, "Intensity-modulated radiation therapy for definitive treatment of cervical cancer : a meta-analysis", Radiat Oncol, 13, pp.177~ (2018)
  23. Wang X, "Adjuvant intensity-modulated radiotherapy(IMRT)with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors : a phase II trial", Eur J Surg Oncol, 41, pp.1082~1088 (2015)
  24. Lou H, "A prospective study of IMRT versus 3D-CRT for post-operative cervical cancer patients", Int J Radiat Oncol Biol Phys, 102(3 Suppl), pp.S85~ (2018)
  25. Schwarz JK, "Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients", Int J Radiat Oncol Biol Phys, 81, pp.1258~1263 (2011)
  26. Chopra S, "Predictors of grade 3 or higher late boweltoxicity in patients undergoing pelvic radiation for cervical cancer : results from a prospective study", Int J Radiat Oncol Biol Phys, 88, pp.630~635 (2014)
  27. Klopp AH, "Patient-reported toxicity during pelvic in¬tensity-modulated radiation therapy : NRG Oncology-RTOG 1203", J Clin Oncol, 36, pp.2538~2544 (2018)
  28. Chopra S, "Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer(PARCER) : a randomized controlled trial", J Clin Oncol, 39, pp.3682~3692 (2021)
  29. Yeung AR, "Improvement in patient-reported outcomes with intensity-modulated radiotherapy(RT)compared with stan-dard RT : a report from the NRG Oncology RTOG 1203 Study", J Clin Oncol, 38, pp.1685~1692 (2020)
  30. Supriya C, "Late toxicity within a Phase III clinical tri¬al of IG-IMRT in cervix cancer(PARCER) : reanalysis with time weighted adverse event reporting(MOSES)", Radiother Oncol, 177, pp.16~20 (2022)
  31. Brixey CJ, "Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies", Int J Radiat Oncol Biol Phys, 54, pp.1388~1396 (2002)
  32. Mell LK, "Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy", Int J Radiat Oncol Biol Phys, 66, pp.1356~1365 (2006)
  33. Rose BS, "Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy", Int J Radiat Oncol Biol Phys, 79, pp.800~807 (2011)
  34. Rose BS, "Correlation between radiation dose to 18F-FDG-PET defined active bone marrow subregions and acute hemato¬logic toxicity in cervical cancer patients treated with chemo¬radiotherapy", Int J Radiat Oncol Biol Phys, 83, pp.1185~1191 (2012)
  35. Noticewala SS, "Longitudinal changes in active bone mar¬row for cervical cancer patients treated with concurrent chemoradiation therapy", Int J Radiat Oncol Biol Phys, 97, pp.797~805 (2017)
  36. Huang J, "Pelvic bone marrow spar¬ing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy : a single-center prospective randomized controlled trial", Radiat Oncol, 15, pp.180~ (2020)
  37. Klopp AH, "Hematologic toxicity in RTOG 0418 : a phase 2 study of postoperative IMRT for gynecologic cancer", Int J Radiat Oncol Biol Phys, 86, pp.83~90 (2013)
  38. Williamson CW, "Positron emission tomography-guided bone mar¬row-sparing radiation therapy for locoregionally advanced cervix cancer : final results from the INTERTECC phase II", III trial, 2022, pp.112, 169~178
  39. Mell LK, "Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer : an International Multicenter Phase II Clini¬cal Trial(INTERTECC-2)", Int J Radiat Oncol Biol Phys, 97, pp.536~545 (2017)
  40. Chino J, "Radiation therapy for cervical cancer : executive summary of an ASTRO Clinical Practice Guide¬line", Pract Radiat Oncol, 10, pp.220~234 (2020)
  41. "Radiation therapy for cervical cancer: an ASTRO Clinical Practice Guideline" (2020)[URL]
  42. Mileshkin LR, "Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the ran¬domized phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)", J Clin Oncol, 39(18 Suppl), pp.LBA3~ (2021)
  43. Holschneider CH, "Brachytherapy : A critical component of pri¬mary radiation therapy for cervical cancer : from the Society of Gynecologic Oncology(SGO)and the American Brachy¬therapy Society(ABS)", Brachytherapy, 18, pp.123~132 (2019)
  44. Potter R, "MRI-guided adaptive brachytherapy in locally advanced cervical cancer(EMBRA-CE-I) : a multicentre prospective cohort study", Lancet Oncol, 22, pp.538~547 (2021)
  45. Potter R, "The EMBRACE II study : the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies", Clin Transl Radiat Oncol, 9, pp.48~60 (2018)
  46. Ito K, "Phase I dose-escalation study of stereotactic body radiotherapy boost for cervical cancer unsuitable for intra-cavitary brachytherapy", Int J Radiat Oncol Biol Phys, 105(1 Suppl), pp.E323~ (2019)
  47. Jullian N, "2022-RA-932-ESGO : Stereotactic body radiotherapy boost as an alternative for locally advanced cervical cancer when brachytherapy is not available, a prospective mono¬centric phase II", Int J Gynecol Cancer, 32(Suppl 2), pp.A34~ (2022)
  48. Bacorro W, "Phase 1", 2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radio¬ therapy for Advanced Cervical cancers INeligible for Chem¬oTherapy(HYACINCT), 2022, pp.61, 688~697
  49. Chino JP, "IDEAL-GYN(Integrated Dose Escalation for Advanced Localized Gynecologic Cancers) : a dose escala¬tion trial of bowel sparing simultaneous integrated boosts for node positive cervical and vulvar cancers", Int J Radiat Oncol Biol Phys, 99(2 Suppl), pp.E286~ (2017)
  50. Cho WK, "A dummy-run evaluation of postoperative hypofractionated intensity-modulated radiation therapy(POHIM-RT)trials for cervical cancer", J Radiat Res, 62, pp.149~154 (2021)
  51. "Hypofractionated external-beam radiOtherapy for intact cervical cancer (HEROICC-Trial): a feasibility study" (2020)[URL]
  52. Sturdza A, "Image guided brachytherapy in locally advanced cervical cancer : improved pelvic control and sur¬vival in RetroEMBRACE, a multicenter cohort study", Radio¬ther Oncol, 120, pp.428~433 (2016)
  53. Arnesen MR, "Short-course PET based simultane¬ous integrated boost for locally advanced cervical cancer", Radiat Oncol, 11, pp.39~ (2016)
  54. Duan J, "Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost : a novel approach for improving cervical tumor dose coverage", Int J Radiat Oncol Biol Phys, 71, pp.765~771 (2008)
  55. Assenholt MS, "Proof of principle : applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical can¬cer", Brachytherapy, 13, pp.361~368 (2014)
  56. Klepczyk L, "Image-based intra¬cavitary brachytherapy with concurrent applicator-guided IMRT boost for cervical cancer", Brachytherapy, 12(Suppl 1), pp.S56~S57 (2013)
  57. Wang X, "Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer", J Contemp Brachytherapy, 8, pp.122~127 (2016)
  58. Lee TH, "Ste¬reotactic ablative body radiotherapy boost for cervical can¬cer when brachytherapy boost is not feasible", Radiat Oncol, 16, pp.148~ (2021)
  59. Albuquerque K, "A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer", Int J Radiat Oncol Biol Phys, 106, pp.464~471 (2020)
  60. Kim H, "Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy : outcome from a multicenter retrospective study(Korean Radiation Oncology Group 1419)", Int J Gynecol Cancer, 28, pp.371~378 (2018)
  61. Gultekin M, "Stereotactic body radiotherapy as a boost in cervical can¬cer : a single-center experience", Int J Radiat Oncol Biol Phys, 108(3 Suppl), pp.E476~ (2020)
  62. Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer", N Engl J Med, 340, pp.1144~1153 (1999)
  63. Keys HM, "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hyster¬ectomy for bulky stage IB cervical carcinoma", N Engl J Med, 340, pp.1154~1161 (1999)
  64. Mendez LC, "Should we embrace hypofractionated radio¬therapy for cervical cancer? A technical note on manage-ment during the COVID-19 pandemic", Radiother Oncol, 148, pp.270~273 (2020)
  65. Komen A, "A retrospective study of advanced carcinoma of the cervix treated with a hypofractionated radiation thera¬py protocol at the department of radiation oncology", pp.2014
  66. Muckaden MA, "Hypofractionated radiotherapy in carcinoma cervix IIIB : Tata Memorial Hospital experience", Indian J Cancer, 39, pp.127~134 (2002)
  67. Viegas CM, "Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical can¬cer patients with stage IIIB disease and bilateral parametrial involvement : a phase I-II study", Int J Radiat Oncol Biol Phys, 60, pp.1154~1159 (2004)
  68. Figueredo Negron CI, "A comparison of intensity-modulated radiotherapy with simultaneous integrated boost with three-dimensional conformal radio¬therapy with sequential boost for locally advanced cervical cancer : a dosimetric study", Cureus, 14, pp.e32940~ (2022)
  69. Ramlov A, "Clinical implementation of coverage probabil¬ity planning for nodal boosting in locally advanced cervical cancer", Radiother Oncol, 123, pp.158~163 (2017)
  70. Boyle J, "Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies", Gynecol Oncol, 135, pp.239~243 (2014)
  71. Jethwa KR, "Lymph node–directed simultaneous inte¬grated boost in patients with clinically lymph node–positive cervical cancer treated with definitive chemoradiotherapy : clinical outcomes and toxicity", J Radiat Oncol, 9, pp.103~111 (2020)
  72. Jiang P, "Image guidance volume-modulated arc radiation therapy concur¬ rently with nab-paclitaxel plus cisplatin for patients with locally advanced cervical cancer : a single-arm dose escalation trial", Int J Radiat Oncol Biol Phys, 115, pp.1197~1204 (2023)
  73. Gouy S, "Nodal-staging surgery for locally advanced cervical cancer in the era of PET", Lancet Oncol, 13, pp.e212~e220 (2012)
  74. Ramirez PT, "Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer : a prospective correlation of surgical findings with positron emission tomography", computed tomography findings, 2011, pp.117, 1928~1934
  75. Vargo JA, "Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer : analysis of regional control and recurrence patterns in the positron emission tomography", computed tomography era, 2014, pp.90, 1091~1098
  76. Bacorro W, "Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer", Gynecol Oncol, 148, pp.461~467 (2018)
  77. Kim JY, "Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases", Int J Radiat Oncol Biol Phys, 84, pp.741~747 (2012)
  78. Kim HS, "Impact of chemoradiation on prognosis in stage IVB cervical cancer with distant lymphatic metastasis", Cancer Res Treat, 45, pp.193~201 (2013)
  79. Ning MS, "Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer", Gynecol Oncol, 148, pp.132~138 (2018)
  80. Macchia G, "Stereotactic body radiotherapy in oligometastatic cervical cancer(MITO-RT2", RAD study) : a collaboration of MITO, AIRO GYN, and MaNGO groups, 2022, pp.32, 732~739
  81. Pirasteh A, "Imaging and its impact on defining the oligometastatic state", Semin Radiat Oncol, 31, pp.186~199 (2021)
  82. Olson R, "Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors(SABR-COMET-3) : study protocol for a randomized phase III trial", BMC Cancer, 20, pp.380~ (2020)
  83. Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors(SABR-COMET-10) : study protocol for a randomized phase III trial", BMC Cancer, 19, pp.816~ (2019)
  84. Sapienza LG, "Pelvic insufficiency fractures after external beam radiation therapy for gynecologic cancers : a meta-analysis and meta-regression of 3929 patients", Int J Radiat Oncol Biol Phys, 106, pp.475~484 (2020)
  85. Ioffe YJ, "Postradiation damage to the pelvic girdle in cervical cancer patients : is intensity-modulated radiation therapy safer than conventional radiation?", Int J Gynecol Cancer, 24, pp.806~812 (2014)
  86. Ramlov A, "Risk factors for pelvic insufficiency fractures in locally advanced cervical cancer following intensity modulated radiation therapy", Int J Radiat Oncol Biol Phys, 97, pp.1032~1039 (2017)
  87. Vitzthum LK, "Risk of pelvic fracture with radiation therapy in older patients", Int J Radiat Oncol Biol Phys, 106, pp.485~492 (2020)
  88. Levine JM, "Infertility in reproductive-age female cancer survivors", Cancer, 121, pp.1532~1539 (2015)
  89. Ghadjar P, "Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation", Radiat Oncol, 10, pp.50~ (2015)
  90. Kovtun KA, "Ovary-sparing radiation planning techniques can achieve ovarian dose reduction for soft tissue sarcoma of the buttock and thigh", Sarcoma, 2017, pp.2796925~ (2017)
  91. Wallace WH, "Predicting age of ovarian failure after radiation to a field that includes the ovaries", Int J Radiat Oncol Biol Phys, 62, pp.738~744 (2005)
  92. Charo LM, "Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients", Mol Oncol, 15, pp.67~79 (2021)
  93. Ferrandina G, "Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer(Lacc)patients : a phase II study", Eur J Surg Oncol, 44, pp.1062~1068 (2018)
  94. Lesnock JL, "Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy : a cost-effectiveness analysis", Gynecol Oncol, 129, pp.574~579 (2013)
  95. Chen LA, "Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers", Gynecol Oncol, 136, pp.521~528 (2015)
  96. Chan P, "Inter-and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy : a cinematic-MRI point-of-interest study", Int J Radiat Oncol Biol Phys, 70, pp.1507~1515 (2008)
  97. Beadle BM, "Cervix regression and motion during the course of external beam chemoradiation for cervical cancer", Int J Radiat Oncol Biol Phys, 73, pp.235~241 (2009)
  98. Jadon R, "A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer", Clin Oncol(R Coll Radiol), 26, pp.185~196 (2014)
  99. Heijkoop ST, "Quantification of intra-fraction changes during radiotherapy of cervical cancer assessed with pre-and post-fraction Cone Beam CT scans", Radiother Oncol, 117, pp.536~541 (2015)
  100. Chopra S, "Vaginal displacement during course of adju¬vant radiation for cervical cancer : results from a prospective IG-IMRT study", Br J Radiol, 87, pp.20140428~ (2014)
  101. Adli M, "Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer?", Int J Radiat Oncol Biol Phys, 57, pp.230~238 (2003)
  102. Chen VE, "The impact of daily bladder filling on small bowel dose for intensity modulated radiation therapy for cervical cancer", Med Dosim, 44, pp.102~106 (2019)
  103. Rios I, "Problems and solutions in IGRT for cervical cancer", Rep Pract Oncol Radiother, 23, pp.517~527 (2018)
  104. Mens JM, "Tumor tracking in cervical cancer patients based on implanted polymeric markers", Int J Radiat Oncol Biol Phys, 81(2 Suppl), pp.S460~ (2011)
  105. Heijkoop ST, "Clinical implementation of an online adaptive plan-of-the-day protocol for nonrigid motion management in locally advanced cervical cancer IMRT", Int J Radiat Oncol Biol Phys, 90, pp.673~679 (2014)
  106. Shelley CE, "Adaptive radiotherapy in the management of cervical can¬cer : review of strategies and clinical implementation", Clin Oncol(R Coll Radiol), 33, pp.579~590 (2021)
  107. Ahmad R, "Increasing treatment accuracy for cervical cancer patients using correlations between bladder-filling change and cervix-uterus displacements : proof of principle", Radiother Oncol, 98, pp.340~346 (2011)
  108. Stewart J, "Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer", Int J Radiat Oncol Biol Phys, 78, pp.350~358 (2010)
  109. Bondar ML, "Individualized nonadaptive and online-adaptive intensity-modulated radiotherapy treatment strate¬gies for cervical cancer patients based on pretreatment ac¬quired variable bladder filling computed tomography scans", Int J Radiat Oncol Biol Phys, 83, pp.1617~1623 (2012)
  110. Novakova E, "What is the optimal number of library plans in ART for locally advanced cervical cancer?", Radiother Oncol, 125, pp.470~477 (2017)
  111. Ahmad R, "A margin-of-the-day online adaptive intensity-modulat¬ed radiotherapy strategy for cervical cancer provides superi¬or treatment accuracy compared to clinically recommended margins : a dosimetric evaluation", Acta Oncol, 52, pp.1430~1436 (2013)
  112. Buschmann M, "Image guided adaptive external beam radiation therapy for cervix cancer : evaluation of a clinically implemented plan-of-the-day technique", Z Med Phys, 28, pp.184~195 (2018)
  113. Hunt A, "Adaptive radiotherapy enabled by MRI guidance", Clin Oncol(R Coll Radiol), 30, pp.711~719 (2018)
  114. Khan AA, "Dosimetric analysis of intracavitary brachytherapy applicators : a practical study", Radiat Oncol J, 40, pp.180~191 (2022)
  115. "A trial comparing intensity modulated radiation therapy (IMRT) with conventional radiation therapy in stage IIB car¬cinoma cervix" (2019)[URL]
  116. Leath CA, "Incorporation of triapine(T)with cispl¬atin chemoradiation(CRT)for locally advanced cervical and vaginal cancer : results from NRG-GY006, a phase III rand¬omized trial", J Clin Oncol, 41(16 Suppl), pp.5502~ (2023)
  117. Monk B, "O001", #504 Durvalumab, in combination with and follow¬ing chemoradiotherapy, in locally advanced cervical cancer : results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial, 2022, pp.32, A2~A3
  118. Mayadev J, "Anti-PD-L1(atezolizumab)as an im¬mune primer and concurrently with extended-field chemo¬radiotherapy for node-positive locally advanced cervical cancer", Int J Gynecol Cancer, 30, pp.701~704 (2020)
  119. Frumovitz M, "Lymphadenectomy in locally advanced cervical cancer study(LiLACS) : phase III clinical trial com¬paring surgical with radiologic staging in patients with stag¬es IB2-IVA cervical cancer", J Minim Invasive Gynecol, 21, pp.3~8 (2014)
  120. Marnitz S, "Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA : oncologic results of a prospective ran¬domized international multicenter(Uterus-11)intergroup study", Int J Gynecol Cancer, 30, pp.1855~1861 (2020)

관련 논문AI추천

Assessment of Tumor Regression by Consecutive Pelvic Magnetic Resonance Imaging and Dose Modification during High- Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix김석모, 나병식, 남택근, 송주영, 안성자, 윤미선, 정웅기, 최호선대한암학회 · Cancer Research and Treatment2005 · 제37권 제3호Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period강성희, 강현철, 김경수, 김재원, 김학재, 김희승, 박노현, 송용상, 엄근용, 위찬우, 이태훈, 정현훈, 최창헌, 이마리아대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy박희철, Akio Yonesaka, Hiroki Shirato, Hiroshi Taguchi, Kazuhiko Tsuchiya, Masayori Ishikawa, Noriaki Sakuragi, Norio Katoh, Rumiko Kinoshita, Shinichi Shimizu, Yasuhiko Ebina연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제1호Clinical outcome after high dose rate intracavitary brachytherapy with traditional point ‘A’ dose prescription in locally advanced carcinoma of uterine cervix: dosimetric analysis from the perspective of computed tomography imaging-based 3-dimensional treatment planningAbhay Chakravarty, Abhishek Basu, Pradip Kumar Maiti, Saikat Sau, Sourav Sau, Suman Dhabal대한산부인과학회 · Obstetrics & Gynecology Science2024 · 제67권 제1호Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?권상훈, 김미영, 김옥배, 김진희, 박승규, 변상준, 오영기대한암학회 · Cancer Research and Treatment2014 · 제46권 제4호Results of Curative Radiotherapy Alone in Patients with Uterine Cervical CarcinomasByung-Sik Nah, Ho-Seon Choi, Sung-Ja Ahn, Taek-Keun Nam, Woong-Ki Chung, Yoon-Kyeong Oh대한암학회 · Cancer Research and Treatment2002 · 제34권 제5호

이 간행물의 다른 논문 (30건)

Longitudinal Changes in Smoking Behaviors and Cancer-Related Mortality Risk in Middle-aged Korean Women김선주, 박보영, 김소연, TRANTHIXUANMAIpp. 18-26Trends and Clinical Characteristics of Next-Generation Sequencing-Based Genetic Panel Tests: An Analysis of Korean Nationwide Claims Data박해용, 임현선, 김은경, 최윤라, 심효섭, 장미, 허자윤pp. 27-36A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial김규현, 이근욱, 안희경, 김진수, 이윤규, 안호정, 임선민, 안명주, 김범석, 김혜련, 이현우pp. 37-47Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset왕장영, 이윤규, 신상원, 최진혁, 이종석, 김진수, 심병용, 김주항, 민영주, 이기형, 이영주, 박건욱, 고윤호, 김동완, 최석영, 강진형, 조은경, 이경원, 전상훈, 이성숙, 이경희, 김상위, 안명주, 조병철pp. 48-60First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data박세훈, 전영경, 정현애, 안진석, 안명주, 이세훈, 선종무pp. 61-69
원문 보기